Somapacitan is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: a Randomised Controlled Phase 3 Study
Hormone Research in Paediatrics · 2025
DOI: 10.1159/000545786 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Hormone Research in Paediatrics, 2025. Verfasst von Junfen Fu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Department, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou…. Hauptthemen laut MEDLINE: Human Growth Hormone, Dwarfism, Pituitary. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
REAL6 is a randomized, multi-centre, open-labelled, active-controlled parallel group phase 3 trial (NCT04970654) investigating once-weekly somapacitan, a reversible albumin-binding growth hormone (GH) derivative, in Chinese children with GH deficiency (GHD).
Methods
110 treatment-naïve patients were randomized 2:1 to somapacitan (0.16 mg/kg/week) or daily GH (Norditropin®; 0.034 mg/kg/day) for 52 weeks. Annualized height velocity (HV; cm/year) at week 52 was the primary measurement. Additional assessments included HV standard deviation score (SDS), height SDS, bone age, insulin-like growth factor-I (IGF¬ I) SDS, and observer-reported outcomes.
Results
Estimated mean HV at week 52 was 11.0 and 10.4 cm/year for somapacitan and daily GH, respectively. Non-inferiority of somapacitan compared to daily GH was confirmed. Changes in HVSDS, height SDS, bone age, and IGF-I SDS from baseline to week 52 were similar between groups. At week 52, mean (SD) IGF-I SDS was within intended reference range (-2.0 to +2.0) and comparable between groups: +0.5 (1.4) for somapacitan versus +0.1 (1.2) for daily GH. Somapacitan was well-tolerated with a safety profile consistent with the well-known safety profile of daily GH. A low proportion of injection-site reactions were reported for somapacitan (2.7%), with no reports of injection-site pain during the 52-week treatment period. Disease burden was reduced from baseline to week 52 for both treatments. Somapacitan reduced treatment burden compared to daily GH.
Conclusions
Efficacy and safety profiles were comparable for Chinese children with GHD treated with somapacitan or daily GH. Both treatments similarly reduced disease burden, while treatment burden was reduced with somapacitan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Department, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, fjf68@zju.edu.cn.
- Department of Pediatric Genetics, Endocrinology and Metabolism, Chengdu Women and Children's Center Hospital, Chengdu, China.
- Clinical Development, Novo Nordisk A/S, Søborg, Denmark.
- Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children Health, Beijing, China.
- Department of PediatrIcs, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou, China.
Zitieren
APA
Fu, J., Cheng, X., Højby, M., Gong, C., Leunbach, T. L., Li, Y., Wei, H., Zhu, Y., Zhang, Y., & Zhong, Y. (2025). Somapacitan is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: a Randomised Controlled Phase 3 Study. Hormone Research in Paediatrics. https://doi.org/10.1159/000545786
Vancouver
Fu J, Cheng X, Højby M, Gong C, Leunbach TL, Li Y, et al. Somapacitan is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: a Randomised Controlled Phase 3 Study. Hormone Research in Paediatrics. 2025. doi:10.1159/000545786
BibTeX
@article{Fu2025,
author = {Fu, Junfen and Cheng, Xinran and Højby, Michael and Gong, Chunxiu and Leunbach, Tina Lund and Li, Yanhong and Wei, Haiyan and Zhu, Yu and Zhang, Yining and Zhong, Yan},
title = {Somapacitan is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: a Randomised Controlled Phase 3 Study},
journal = {Hormone Research in Paediatrics},
year = {2025},
doi = {10.1159/000545786}
}
EUVIMED